Psoriasis Market: Epidemiology, Therapies, Companies, DelveInsight | Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies,

Psoriasis emerging therapies, such as Imsidolimab, TAK-279, Sonelokimab, and others, are expected to boost the psoriasis Market in the upcoming years.

DelveInsight has launched a new report on "Psoriasis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the psoriasis, historical and forecasted epidemiology as well as the psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover more about the psoriasis disease, diagnosis, and treatment options @ https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Psoriasis Market Report:

Psoriasis affects between 1% and 8% of the global population and begins in childhood in about one-third of cases.
In the United States, an estimated 8 million individuals were diagnosed with psoriasis in 2023. Among these, around 68% had plaque psoriasis, making it the most common form, followed by inverse psoriasis.
Additionally, in 2023, approximately 28% of U.S. psoriasis patients were estimated to have genital psoriasis, with scalp psoriasis also being a common subtype.
In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. BIMZELX is notable for being the first and only approved treatment that targets both IL-17A and IL-17F.
Key Psoriasis companies such as Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, and others are evaluating new drugs for Psoriasis to improve the treatment landscape.
Promising Psoriasis therapies include Imsidolimab, TAK-279, Sonelokimab, and others.

Psoriasis Overview

Psoriasis is a long-term, immune-driven inflammatory skin condition marked by the development of papules and plaques. It results from an overactive immune system, which triggers inflammation and accelerates the skin cell turnover process.

The most prevalent form is plaque psoriasis, while other less common types include inverse, pustular, guttate, and erythrodermic psoriasis.

Although there is currently no cure, several effective treatments are available. Topical therapies remain the standard approach, particularly for mild to moderate cases, often involving glucocorticoids, vitamin D analogs, and sometimes phototherapy. More severe forms typically require systemic treatments.

Psoriasis Market Outlook

Psoriasis is a chronic, relapsing condition that often requires ongoing, long-term treatment. The choice of therapy depends on several factors, including disease severity, associated comorbidities, and access to healthcare. Patients are generally classified as having either mild or moderate-to-severe psoriasis, based on lesion severity, the extent of body surface area affected, and the impact on quality of life.

The current treatment landscape is dominated by TNF inhibitors, interleukin inhibitors, and vitamin D analogs. Market growth is being fueled by the rising use of biologics, a growing focus on personalized medicine, and broader availability of topical treatments. Recent approvals of oral TYK2 inhibitors and nonsteroidal topical therapies have further diversified treatment options, intensifying market competition.

**BIMZELX (bimekizumab-bkzx)** is a monoclonal antibody developed to treat autoimmune conditions such as moderate to severe plaque psoriasis. Its distinct mechanism involves dual inhibition of interleukin-17A and interleukin-17F, key cytokines in the inflammatory pathway. In October 2023, the U.S. FDA approved BIMZELX for adults eligible for systemic therapy or phototherapy.

Discover how the psoriasis market is growing in the coming years @ https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Psoriasis Therapies and Key Companies
Imsidolimab: AnaptysBio
TAK-279: Nimbus Lakshmi/Takeda
Sonelokimab: MoonLake Immunotherapeutics

To know more about the emerging therapies and companies that will drive the psoriasis treatment market, click: https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Psoriasis Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Psoriasis Companies: Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, and others
Key Psoriasis Therapies: Imsidolimab, TAK-279, Sonelokimab, and others
Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Psoriasis Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement

Key benefits of the Psoriasis market report:
The Psoriasis market report covers a descriptive overview and comprehensive insight of the Psoriasis Epidemiology and Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan)..)
The Psoriasis market report provides insights intoon the current and emerging therapies.
The Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Psoriasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psoriasis market.

Got queries? Click here to know more about the Psoriasis Market Landscape https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Psoriasis Patient Share (%) Overview at a Glance
5. Psoriasis Market Overview at a Glance
6. Psoriasis Disease Background and Overview
7. Psoriasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Psoriasis
9. Psoriasis Current Treatment and Medical Practices
10. Unmet Needs
11. Psoriasis Emerging Therapies
12. Psoriasis Market Outlook
13. Country-Wise Psoriasis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Psoriasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Psoriasis Market Outlook 2034 https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Psoriasis Pipeline Insights, DelveInsight

"Psoriasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psoriasis market. A detailed picture of the Psoriasis pipeline landscape is provided, which includes the disease overview and Psoriasis treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.